



Vivoryon Therapeutics Announces Notice of its Annual General Meeting of Shareholders to be Held on June 28, 2021

HALLE (SAALE) / MUNICH, GERMANY, May 17, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (**Vivoryon**) invites all shareholders to Vivoryon's annual general meeting of shareholders to be held on Monday, June 28, 2021 at 10:30 a.m. (CEST).

In accordance with the Temporary Act COVID-19 Justice and Safety (*Tijdelijke wet COVID-19 Justitie en Veiligheid*) (the **COVID Act**), shareholders can only attend the meeting virtually through an audio webcast via the company's website.

All relevant documents are available on the company's website:

<https://www.vivoryon.com/ordinary-general-meeting-of-shareholders-2021/>

NOTE:

If the duration of COVID Act is not extended beyond May 31, 2021, the annual general meeting will be held on Monday, June 28, 2021 at 10:30 a.m. (CEST) as a hybrid meeting both virtually through an audio webcast via the company's website, at <https://www.vivoryon.com/ordinary-general-meeting-of-shareholders-2021/>, and physically at Hilton Amsterdam Airport Schiphol, Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.

###

For more information, please contact:

Vivoryon Therapeutics N.V.

Dr. Manuela Bader, Director IR & Communication

Tel: +49 (0)345 555 99 30

Email: contact@vivoryon.com

Trophic Communications

Gretchen Schweitzer / Valeria Fisher

Tel: +49 (0)172 861 8540 or +49 (0)175 8041816

Email: vivoryon@trophic.eu

About Vivoryon Therapeutics N.V.

With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon is advancing its lead product, varoglutamstat (PQ912), in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In addition, the company pursues a development program for Mepripin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury.



www.vivoryon.com

Forward Looking Statements

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics N.V. as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.